Filing Flows › Humacyte (HUMA) › Q2 2026
Humacyte (HUMA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Humacyte (HUMA) reported revenue of $406K for the second quarter 2026 (Q2 2026), +35% from a year earlier and -18% from the quarter before.
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $406K | -18% | +35% |
| Operating profit | −$27.0M | — | — |
| Net earnings | −$36.8M | — | — |
| Operating cash flow | −$22.1M | — | — |
What changed
Revenue was $406K in Q2 2026, up 35% year over year and down 18% from the previous quarter.
Operating costs exceeded revenue by $27.0M, an operating margin of -6649.3%. Total costs fell 9% while revenue rose 35%. The fastest-growing cost line was Cost of revenue (+478%). The quarter ended with a net loss of $36.8M, wider than the previous quarter's $17.6M loss.
Operating cash flow was −$22.1M. Non-cash charges added back $1.3M of depreciation and $2.6M of share-based compensation. Working capital and other items added $10.8M. Capital expenditures of $104K exceeded it, leaving free cash flow of −$22.2M.
Questions
What was Humacyte's revenue in the second quarter 2026?
Humacyte (HUMA) reported revenue of $406K for the second quarter 2026 (Q2 2026), +35% from a year earlier and -18% from the quarter before.
Source: Humacyte 10-Q on SEC EDGAR.